Skip to main content

Advertisement

Table 3 Proportion of doses being selected as ED90 of Bayesian Emax and NDLM model at different dose response curves in the Half Adaptive design settings (Scenario 3)

From: Design considerations and analysis planning of a phase 2a proof of concept study in rheumatoid arthritis in the presence of possible non-monotonicity

  Dose Level (mg/kg)
0.03 0.3 3 10 20 30
Bayesian Emax Model
 Proportion of doses being selected as ED90
  Flat placebo like Curvea 0% 0% 0% 0% 38% 0%
   Emax like Curve 0% 0% 0% 0% 89% 11%
  Log Linear Curve 0% 0% 0% 0% 81% 19%
  U-Shape Curvea 0% 0% 0% 0% 64% 0%
Bayesian NDLM Model
 Proportion of doses being selected as ED90
  Flat placebo like curve 16% 17% 14% 14% 11% 12%
   Emax like Curve 1% 1% 14% 25% 35% 26%
  Log Linear Curve 1% 1% 5% 11% 29% 54%
  U-Shape Curve 2% 42% 48% 5% 2% 0%
  1. aED90 is missing where the maximum dose was not estimated correctly